Emerging therapies for the treatment of relapsed or refractory multiple myeloma.
作者： Meletios A. Dimopoulos , Jesus F. San-Miguel , Kenneth C. Anderson
DOI: 10.1111/J.1600-0609.2010.01542.X
关键词:
摘要: Encouraging progress has been made in the treatment of patients with relapsed/refractory multiple myeloma (MM). The rapidly evolving understanding key pathways responsible for tumor growth and survival led to development novel agents (including immunomodulatory drugs, proteasome inhibitors, histone deacetylase other targeted agents) potential provide significant improvements response survival, influence guidelines. This review summarizes recent advances biology MM clinical trials that are currently under investigation this disease.
myeloma.org参考文章(117)
Claire M. Edwards, Junling Zhuang, Gregory R. Mundy, The pathogenesis of the bone disease of multiple myeloma Bone. ,vol. 42, pp. 1007- 1013 ,(2008) , 10.1016/J.BONE.2008.01.027
Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W. B. van Leeuwen, Asher A. Chanan-Khan, Robert Z. Orlowski, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood. ,vol. 110, pp. 3281- 3290 ,(2005) , 10.1182/BLOOD-2007-01-065888
Roland Fenk, Mark Michael, Fabian Zohren, Thorsten Graef, Akos Czibere, Ingmar Bruns, Frank Neumann, Barbara Fenk, Rainer Haas, Guido Kobbe, Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma Leukemia & Lymphoma. ,vol. 48, pp. 2345- 2351 ,(2007) , 10.1080/10428190701694194
Donna M. Weber, Christine Chen, Ruben Niesvizky, Michael Wang, Andrew Belch, Edward A. Stadtmauer, David Siegel, Ivan Borrello, S. Vincent Rajkumar, Asher Alban Chanan-Khan, Sagar Lonial, Zhinuan Yu, John Patin, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America The New England Journal of Medicine. ,vol. 357, pp. 2133- 2142 ,(2007) , 10.1056/NEJMOA070596
H. M. Lokhorst, O. J. A. Th. Meuwissen, E. J. E. G. Bast, A. W. Dekker, VAD chemotherapy for refractory multiple myeloma. British Journal of Haematology. ,vol. 71, pp. 25- 30 ,(1989) , 10.1111/J.1365-2141.1989.TB06269.X
Constantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, Robert Schlossman, Masaharu Akiyama, Dharminder Chauhan, Teru Hideshima, Steven P Treon, Nikhil C Munshi, Paul G Richardson, Kenneth C Anderson, Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. ,vol. 21, pp. 5673- 5683 ,(2002) , 10.1038/SJ.ONC.1205664
J. Ferlay, D.M. Parkin, E. Steliarova-Foucher, Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer. ,vol. 46, pp. 765- 781 ,(2010) , 10.1016/J.EJCA.2009.12.014
Steven K. Teo, Properties of thalidomide and its analogues: implications for anticancer therapy. Aaps Journal. ,vol. 7, ,(2005) , 10.1208/AAPSJ070103
Leslie A. Kalish, Robert A. Kyle, Richard G. Hahn, Douglas C. Tormey, Martin M. Oken, Morie A. Gertz, Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology. ,vol. 18, pp. 475- 480 ,(1995) , 10.1097/00000421-199512000-00003
J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan, S V Rajkumar, B G M Durie, , J-L Harousseau, International uniform response criteria for multiple myeloma Leukemia. ,vol. 20, pp. 1467- 1473 ,(2006) , 10.1038/SJ.LEU.2404284